$GILD News

Last published 2h ago

2h agoGILDFeds arrest top official of healthcare company, alleging illegal drug importationCNBCU.S. officials are accusing two top officials of a Canadian company of operating a scheme to illegally import prescription drugs, court records show.
2d agoLEGN GILD AZN MCK+4Gabelli Releases Agenda for 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
1w agoGILDGILEAD SCIENCES, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoGILDGilead Sciences Announces Third Quarter 2026 Financial ResultsBusiness WireProduct Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion Biktarvy Sales Increased 10% Year-Over-Year to $4.1 Billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations
2w agoLEGN GILD AZN MCK+5Gabelli To Host 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
2w agoGILDGilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBDBusiness Wire-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio -- -- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead
2w agoGILDGilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026Business Wire- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Cholangitis (PBC)
3w agoGILDGilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026Business Wire– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment – – Real-World Evidence Provides Insight into Early U.S. Adoption of
3w agoGILDGilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Business WireGilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day,
1mo agoGILD SMMT AZN MRKAstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investmentCNBCPascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
1mo agoGILDGilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV PreventionBusiness Wire- 6 Royalty-Free Voluntary Licensing Agreements Aim to Support Potential Manufacturing Readiness and Supply in 120 High-Incidence, Resource-Limited Countries Ahead of Phase 3 PURPOSE 365 Results and Potential
1mo agoGILDGilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the CaribbeanBusiness Wire– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention – – Partnership Advances Gilead’s Global Access Strategy, Helping Turn
1mo agoNNVC GILD MRNA PFE+1A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
2mo agoGILDGilead Opens State-of-the-Art Research Center to Advance the Next Generation of MedicinesBusiness Wire– Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration –– One of Three Foster City Projects Supporting Gilead’s $32 Billion U.S. Investment and 3,000 High-Quality
2mo agoGILDU.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensBusiness Wire– Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing
2mo agoGILDApproval of Bixlenvo, Nda #221104 (Type 4 - New Combination)FDA Approved DrugsApproval Date: 08/27/2026; Drug Name: Bixlenvo, Nda #221104; Active Ingredients: BICTEGRAVIR AND LENACAPAVIR; Company: Gilead Sciences; Submission Status: Approval; Submission Classification: Type 4 - New Combination; Application Number: 221104
2mo agoGILDApproval of Sunlenca, Nda #215974 (Efficacy)FDA Approved DrugsApproval Date: 08/27/2026; Drug Name: Sunlenca, Nda #215974; Active Ingredients: LENACAPAVIR SODIUM; Company: Gilead Sciences Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 215974
2mo agoGILDApproval of Sunlenca, Nda #215973 (Efficacy)FDA Approved DrugsApproval Date: 08/27/2026; Drug Name: Sunlenca, Nda #215973; Active Ingredients: LENACAPAVIR SODIUM; Company: Gilead Sciences Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 215973
2mo agoGILDGilead Sciences to Present at Upcoming Third Quarter 2026 Investor ConferencesBusiness WireGilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday, September 9 at 11:00 AM Eastern
2mo agoGILDEuropean Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 StatusBusiness Wire– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval Establishes Trodelvy as the First and Only Antibody-Drug
2mo agoGILDCourt rules companies can't import Gilead medications from overseas in blow to AFP health programsCNBCA U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.
3mo agoGILDCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial ResultsBusiness WireProduct Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was
3mo agoGILDApproval of Veklury, Nda #214787 (Labeling)FDA Approved DrugsApproval Date: 07/29/2026; Drug Name: Veklury, Nda #214787; Active Ingredients: REMDESIVIR; Company: Gilead Sciences Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214787
3mo agoGILDCHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast CancerBusiness Wire– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically
3mo agoGILDGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026Business WireGilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day,
3mo agoGILD MRKInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral TherapyBusiness Wire– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials – – ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment – Gilead
3mo agoGILD MRKGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and CureBusiness Wire– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the
4mo agoGILDU.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast CancerBusiness Wire– Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – – Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast
4mo agoONNVF MRK PFE GSK+1Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category
4mo agoGILDEuropean Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 InhibitorsBusiness Wire–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on
5mo agoGILDGilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak ReliefBusiness WireGilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo
5mo agoGILDNational AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community LeadershipBusiness Wire- Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement's history for future generations - The National AIDS Memorial together with the
5mo agoGILD MRKGilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV TreatmentBusiness Wire– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead's Lenacapavir,
5mo agoGILD MRKMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 StudyBusiness WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
5mo agoGILDGilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South AfricaBusiness WireGilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access
5mo agoGILD LKFTGILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINEGlobeNewswireCompanies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET –
5mo agoGILD LKFTGilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation PipelineBusiness Wire– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV
5mo agoGILDGilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)Business Wire– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA – – 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated
5mo agoGILDPhase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)Business Wire– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression – – Further Analyses of the Phase 3 ASSURE Study Demonstrate
5mo agoGILDFDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)Business Wire– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – – Approval introduces the first FDA-approved therapy for this
5mo agoGILDGilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 InhibitorsBusiness Wire– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive
5mo agoGILDApproval of Hepcludex, Bla #761468FDA Approved DrugsApproval Date: 05/22/2026; Drug Name: Hepcludex, Bla #761468; Active Ingredients: BULEVIRTIDE-GMOD); Company: Gilead Sciences Inc; Submission Status: Approval; Application Number: 761468
5mo agoGILDFDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) InfectionFDA Press ReleasesToday, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis ...
5mo agoGILDNew ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in OncologyBusiness Wire– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include
5mo agoGILDGilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology PortfolioBusiness Wire– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful
5mo agoGILDGilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic DiseaseBusiness Wire- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year - Gilead Sciences, Inc. (NASDAQ:GILD) today announced a renewed five-year collaboration with the World Health
5mo agoGILDApproval of Biktarvy, Nda #210251 (Manufacturing (CMC))FDA Approved DrugsApproval Date: 05/21/2026; Drug Name: Biktarvy, Nda #210251; Active Ingredients: BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE; Company: Gilead Sciences Inc; Submission Status: Approval; Submission Classification: Manufacturing (CMC); Application Number: 210251
6mo agoGILDGilead Prices $3 Billion of Senior Unsecured NotesBusiness WireGilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate
6mo agoGILDGilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026Business Wire- Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across
6mo agoGILD GILSCIGilead Sciences Q1 2026 Earnings Conference CallGILEAD SCIENCES INCEarnings Call TranscriptsGood afternoon, everyone, and welcome to Gilead's first quarter 2026 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks, followed by our Q&A session. Ple